ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder worldwide. Despite its increasing prevalence, MASLD is often asymptomatic in its early course, leading to considerable underdiagnosis. Insulin resistance (IR) plays a key role in MASLD development; however, the incremental value of IR-related biomarkers in machine learning (ML) diagnostic models for MASLD has not been fully investigated. Methods: This retrospective single-center study included 18,535 adults (5992 with MASLD and 12,543 without MASLD) undergoing routine health examinations at our research center. Two feature sets were created: Set 1 included demographic, anthropometric, clinical, and biochemical indicators, while Set 2 further incorporated IR-related biomarkers, including triglyceride-glucose (TyG)-based indices and the metabolic score for insulin resistance (METS-IR). Six ML algorithms were used to develop diagnostic models. Model performance was assessed using sensitivity, specificity, F1-score, and area under the curve (AUC) on the training and validation sets, with clinical utility evaluated using decision curve analysis (DCA). Model interpretability was further explored using Shapley Additive exPlanations (SHAP). Results: All six ML models demonstrated a statistically significant improvement in AUC values after incorporating IR-related biomarkers (all P < 0.05). In the validation set, the extremely randomized trees (ERT) model with Set 2 achieved the highest AUC (0.901). DCA further indicated that models incorporating IR-related biomarkers generally provided a higher net clinical benefit. Overall, the ERT model provided the most favorable combination of discrimination and clinical utility. SHAP analysis further emphasized the important role of IR-related biomarkers in MASLD diagnosis. Conclusion: Incorporating IR-related biomarkers into ML diagnostic models improved the accuracy and clinical utility of MASLD detection without increasing testing costs or patient burden. These findings highlight the incremental diagnostic value of IR-related biomarkers in ML models and support their use as a decision-support tool for MASLD screening in general populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.